Company Overview of Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease and raised transaminases, as well as for the treatment of patients with severe alcoholic hepatitis. The company was founded in 2005 and is headquartered in San ...
16745 West Bernardo Drive
San Diego, CA 92127
Founded in 2005
Key Executives for Conatus Pharmaceuticals Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $473.8K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Total Annual Compensation: $373.6K
Co-Founder, Chief Financial Officer, Senior Vice President of Finance and Secretary
Total Annual Compensation: $302.6K
Compensation as of Fiscal Year 2015.
Conatus Pharmaceuticals Inc. Key Developments
Conatus Pharmaceuticals Inc. - Special Call
Dec 19 16
To discuss the collaboration and license agreement and update the emricasan development program
Conatus Pharmaceuticals Inc. Announces Board Changes
Dec 19 16
On December 19, 2016, Shahzad Malik, M.D. resigned from the Board of Directors of Conatus. In connection with this resignation, pursuant to Conatus' bylaws, the Board voted to decrease the size of the Board from seven to six members. The Board appointed James Scopa as the chair of the Audit Committee to replace Dr. Malik as the Audit Committee chair. The Board also determined that Mr. Scopa qualifies as an audit committee financial expert" as that phrase is defined under the regulations promulgated by the SEC. Further, the Board appointed Daniel L. Kisner, M.D. as a member of the Audit Committee.
Conatus Pharmaceuticals Inc. Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan with Novartis
Dec 19 16
Conatus Pharmaceuticals Inc. announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis, Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis. Conatus is eligible to receive significant payments if certain development, regulatory and commercial milestones are met. Furthermore, Conatus is eligible to receive tiered double digit royalties on emricasan single agent sales and tiered single to double digit royalties on sales of combination products containing emricasan. Conatus has the option to co-commercialize emricasan in the United States, including combination therapies, on a cost-sharing and revenue-sharing basis in lieu of U.S. royalties and with reduced ex-U.S. royalties. Conatus retains limited rights to develop other pan-caspase inhibitors. In addition, Novartis will pay 50% of Conatus’ Phase 2b emricasan development costs after the option exercise, including the planned ENCORE-LF trial in decompensated NASH cirrhosis which, under the current development plan consistent with recent regulatory agency recommendations, will be conducted as Phase 2b rather than Phase 2b/3. Phase 2b emricasan development costs also encompass the ongoing ENCORE-PH trial in primarily compensated NASH cirrhosis, POLT-HCV-SVR trial in post-transplant HCV fibrosis and cirrhosis, and ENCORE-NF trial in NASH fibrosis. Novartis will assume full responsibility for emricasan’s Phase 3 development and all combination product development.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 19, 2016